Here are five key takeaways for regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer ...

Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...

Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit. While essential thrombocythemia (ET) is classified as ...

We are at a critical crossroads for the clinical use of ctDNA in early-stage breast cancer, according to Dr. Heather A. Parsons. “What if we could reliably identify molecular re ...

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

While Enhertu (trastuzumab deruxtecan, T-DXd) is an established treatment for patients with HER2-low metastatic breast cancer (mBC), there has been limited information about how well it works for ...

Resilience plays a key role in helping patients adjust after cancer treatment ends, according to Frank Penedo, professor of ...

Long-term results from a phase 2 study presented at the 27th European Congress on Gynaecological Oncology (ESGO 2026) in Hong ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...

The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...